Trial Profile
A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Apitolisib (Primary) ; Ipatasertib (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms A. MARTIN study
- Sponsors Genentech
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 07 Sep 2022 Status changed from active, no longer recruiting to completed.
- 25 Jul 2022 Planned End Date changed from 1 Jul 2022 to 31 Aug 2022.